Kamada Ltd. (KMDA)

Profitable, cash-generative specialty biopharma with improving margins and a net-cash balance sheet. Trajectory remains positive into 2026 (Q2 2026 revenue +23% YoY per SEC-furnished interim release), and liquidity metrics look strong (current ratio ~4.06, Altman Z-Score ~3.52, interest coverage ~26.84). Valuation appears reasonable (P/E ~20.60, EV/EBITDA ~10.42, FCF yield ~5.82%), with an analyst consensus target of $13 vs $7.89. Main risks disclosed in SEC filings are product concentration, plasma/third-party supply dependence, regulatory exposure, and Israel geopolitical risk; an upcoming $0.17 dividend ex-date (2026-08-27) is within a short holding window but is not large enough to trigger the dividend gate.

A same-day, announced product catalyst — CDC-documented rise in U.S. rabies exposures with Kamada confirming sufficient KedRAB supply — is offset by a fresh bearish insider signal (co-founder/deputy chairman David Tsur sold 177,173 shares Sep 7–9, scored −0.3/−0.4 across four outlets), leaving the media delta determinate-negative (baseline +0.25 → scoring −0.08, on-topic core clearly negative) and retail absent; the conflicting-catalyst moderate red-flag cap applies.

Bullish trend structure with real momentum: price 8.67 closed above SMA20 (8.29), SMA50 (7.64), SMA200 (7.88), EMA9 (8.28) and EMA21 (8.14) after a +5.9% catalyst breakout on 2026-09-17 (CDC/KedRAB demand-supply PR), with RSI14 62.8, Williams %R -9.4 and MACD line 0.17 above zero but still under its signal 0.20 (histogram -0.02, improving from -0.06). Weak confirmations: ADX14 23.6 below the 25 trend-strength threshold and thin volume. Decisive disqualifier is liquidity: 20-day average dollar volume ~$1.35M versus the $5.0M floor, and the recent 3-session regular-session average ~$0.94M versus the $1.5M recent-liquidity floor. Chart quality scores 4; the trade is Do Nothing on liquidity.